Mimicking opioid analgesia in cortical pain circuits.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oswell Corinna S, Rogers Sophie A, James Justin G, McCall Nora M, Hsu Alex I, Salimando Gregory J, Mahmood Malaika, Wooldridge Lisa M, Wachira Meghan, Jo Adrienne, Ortega Raquel Adaia Sandoval, Wojick Jessica A, Beattie Katherine, Farinas Sofia A, Chehimi Samar N, Rodrigues Amrith, Wu Jacqueline K, Ejoh Lindsay L, Kimmey Blake A, Lo Emily, Azouz Ghalia, Vasquez Jose J, Banghart Matthew R, Beier Kevin T, Creasy Kate Townsend, Crist Richard C, Ramakrishnan Charu, Reiner Benjamin C, Deisseroth Karl, Yttri Eric A, Corder Gregory
Аннотация
The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, yet how opioid analgesics modulate this cortical circuit remains unclear. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviors and is selectively modulated by morphine. Using deep-learning behavioral analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective-motivational behaviors without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic mu-opioid receptor promoter to drive chemogenetic inhibition. This opioid-mimetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management targeting a key nociceptive cortical opioid circuit with safe, on-demand analgesia.